Last updated 2 months ago

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

276 patients around the world
Available in United States, Brazil
Subjects diagnosed with SCABP and requiring critical care measures, will receive either 2 intravenous infusions of CAL02 (13.7 to 24 mg/kg bracketed dose by weight), administered 24-26 hours apart or 2 intravenous infusions of placebo. Additionally, all subjects will receive standard of care (SOC) therapy for SCABP, according to scientific guidelines. Critical care measures provide intensive and specialized medical and nursing care, a capacity for continuous monitoring 24 hours/day, and multiple modalities of physiologic organ support to sustain life in seriously/critically ill patients.
Eagle Pharmaceuticals, Inc.
1Research sites
276Patients around the world

This study is for people with

Pneumonia
Bacterial pneumonia

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Sites

Fundação Faculdade Regional de Medicina de São José do Rio Preto
Recruiting
Av. Brg. Faria Lima, 5544 Sao Jose do Rio Preto - Estado de São Paulo 15090-000
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy